Iterum Therapeutics plc (ITRMF) EBITDA Margin (2017 - 2025)
Iterum Therapeutics (ITRMF) posted quarterly EBITDA Margin of 1982.31% for Q3 2025, up 96.42% quarter-over-quarter from 55313.51% in Q1 2019.
Iterum Therapeutics plc (ITRMF) EBITDA Margin (2017 - 2025) Analysis & Trends
Iterum Therapeutics' EBITDA Margin history runs 4 years deep, the most recent figure standing at 1982.31% for Q3 2025.
- In Q3 2025, EBITDA Margin changed N/A year-over-year to 1982.31%; the TTM figure through Sep 2025 stood at 5292.31% (changed N/A YoY), while the FY2019 annual figure was 275732.43%, down 26692242.0% from the prior year.
- EBITDA Margin for Q3 2025 stood at 1982.31%, up from 55313.51% in the prior quarter.
- The five-year high for EBITDA Margin was 1982.31% in Q3 2025, with the low at 1982.31% in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,982.31% |
| Mar 31, 2019 | -55,313.51% |
| Dec 31, 2018 | -10,017.99% |
| Sep 30, 2018 | -9,837.01% |
| Jun 30, 2018 | -8,338.38% |
| Mar 31, 2018 | -6,389.01% |
| Dec 31, 2017 | -2,637.25% |
| Sep 30, 2017 | -5,217.61% |